Ciphergen Faces Nasdaq Delisting for Low Market Cap | GenomeWeb

NEW YORK, June 1 (GenomeWeb News) - The Nasdaq exchange told Ciphergen Biosystems last week that it risks being delisted because its market cap has remained below $50 million for 10 consecutive business days.

 

Ciphergen yesterday said it has until June 23 to regain compliance. Its market cap currently stands at $41.4 million, according to Nasdaq.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In Science this week: intellectual property landscape of CRISPR genome editing, and more.

A researcher has been convicted of conspiring to steal genetically engineered rice, Reuters reports.

Harvard Medical School's George Church says a woolly mammoth-elephant hybrid is only a few years away, according to the New Scientist.

Intel is ending its sponsorship of the International Science and Engineering Fair, the New York Times reports.